Initiatives to Ensure Safety in Cell Therapy

Recently, at a clinic in Tokyo (hereinafter referred to as "the Clinic") that was providing Regenerative medicine in accordance with the Act on Ensuring the Safety Regenerative medicine, etc., a patient died during treatment with autologous adipose-derived stem cells for chronic pain (hereinafter referred to as "the Incident"). We offer our deepest condolences to the deceased patient and their family.

Following this incident, on August 29, 2025, an order was issued to temporarily suspend the provision of related Regenerative medicine at the clinic in question, as well as the manufacture of specific cell-processed products at the specific cell-processed product manufacturing facility. This incident has been reported by multiple media outlets.

Our company has no involvement whatsoever in this matter, and our group's specific cell-processed product manufacturing facilities have not received any orders to temporarily suspend the manufacture of specific cell-processed products.

Following this incident, we have re-evaluated the risks related to quality and safety within our company and have determined that there are no issues with continuing our mesenchymal stem cell culture contract services. We will continue to provide services with safety as our top priority.

Our company provides cell culture contract services at a facility authorized under the Act on Ensuring the Safety of Regenerative medicine, etc. We will continue to prioritize patient safety and strive to provide Regenerative medicine and other related services in a trustworthy manner.